Navidea biopharmaceuticals announces details of presentation at upcoming society for immunotherapy of cancer annual meeting

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced details of the results from the company's ongoing preclinical studies evaluating targeted immunotherapy for cancer based on the manocept platform.
NAVB Ratings Summary
NAVB Quant Ranking